These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12482567)

  • 1. PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
    Ceska R; Stulc T; Zima T; Malbohan I; Fialova L
    Atherosclerosis; 2003 Jan; 166(1):195-6. PubMed ID: 12482567
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
    Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
    Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
    Moriarty PM; Backes JM
    Atherosclerosis; 2003 Jan; 166(1):201. PubMed ID: 12564455
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecule of the month.
    Lindsley CW
    Curr Top Med Chem; 2008; 8(12):1100. PubMed ID: 18693392
    [No Abstract]   [Full Text] [Related]  

  • 5. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
    Miedema MD; Conover CA; MacDonald H; Harrington SC; Oberg D; Wilson D; Henry TD; Schwartz RS
    Am J Cardiol; 2008 Jan; 101(1):35-9. PubMed ID: 18157962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
    Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
    Melenovsky V; Wichterle D; Simek J; Malik J; Haas T; Ceska R; Malik M
    Am J Cardiol; 2003 Aug; 92(3):337-41. PubMed ID: 12888150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of statin and fibrate combination therapy in lipid management.
    Kota SK; Meher LK; Rao ES; Jammula S; Modi KD
    Diabetes Metab Syndr; 2012; 6(3):173-4. PubMed ID: 23158983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
    Okopien B; Huzarska M; Kulach A; Stachura-Kulach A; Madej A; Belowski D; Zielinski M; Herman ZS
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients.
    Coban E; Sari R
    Endocr Res; 2004 Aug; 30(3):343-9. PubMed ID: 15554350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
    Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
    J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
    Tekin A; Tekin G; Güzelsoy D; Kaya A; Gürel CV; Yiğit Z; Ulutin T
    Am J Cardiol; 2004 Jul; 94(2):206-9. PubMed ID: 15246903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.
    Korolenko TA; Cherkanova MS; Tuzikov FV; Johnston TP; Tuzikova NA; Loginova VM; Kaledin VI
    J Pharm Pharmacol; 2011 Jun; 63(6):833-9. PubMed ID: 21585382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
    Van JT; Pan J; Wasty T; Chan E; Wu X; Charles MA
    Am J Cardiol; 2002 Jun; 89(11):1306-8. PubMed ID: 12031735
    [No Abstract]   [Full Text] [Related]  

  • 16. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
    Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
    J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.
    Hirschfield G
    Thromb Haemost; 2001 Jan; 85(1):189-90. PubMed ID: 11204580
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
    Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
    Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
    Gómez-Gerique JA; Ros E; Oliván J; Mostaza JM; Vilardell M; Pintó X; Civeira F; Hernández A; da Silva PM; Rodriguez-Botaro A; Zambón D; Lima J; Díaz C; Aristegui R; Sol JM; Chaves J; Hernández G;
    Atherosclerosis; 2002 Jun; 162(2):245-51. PubMed ID: 11996943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.